See the DrugPatentWatch profile for Stelara
How fast have Stelara biosimilars been selling after launch?
Stelara (ustekinumab) biosimilars’ uptake has generally depended on how each product was positioned at launch—especially pricing versus the reference drug, contracting with pharmacy benefit managers (PBMs), and the degree to which prescribers adopt the biosimilar instead of staying on originator therapy. Those market dynamics vary by country and payer mix, so uptake is often uneven across regions.
What drives commercial uptake for ustekinumab (Stelara) biosimilars?
Commercial performance typically tracks several forces that can change in the first year after launch:
- Payer and PBM incentives: Preferential formularies, step edits, and rebates can shift prescribing quickly if the biosimilar is placed in the same tier as (or ahead of) reference Stelara.
- Price discount and contracting: Larger discounts and broader coverage usually correlate with higher share over time.
- Switching policies: If payers require switching from Stelara to the biosimilar (or make it easy), uptake rises faster.
- Provider confidence and operational experience: Physicians are more likely to switch when biosimilar interchangeability policies are clear and when safety/efficacy data are well understood.
- Indication-by-indication adoption: Uptake can differ across psoriasis, psoriatic arthritis, and Crohn’s disease depending on treatment patterns and payer rules.
Which biosimilars compete against Stelara, and how does that affect share?
Multiple biosimilars can split demand, but the “winner” is often the product with the most favorable contracting terms and formulary placement rather than the one with the earliest or most widely perceived clinical parity. In practice, commercial share can be shaped by how quickly each biosimilar gains:
- preferred formulary status,
- support for prior authorization pathways,
- and pharmacy channel penetration.
What does uptake look like in major markets (US vs. EU vs. other regions)?
Uptake patterns usually differ by market regulation and tender systems:
- In the US, payer contracting and PBM formulary decisions can drive rapid movement once discounts and coverage are set.
- In parts of Europe, tendering and national reimbursement frameworks can cause steep shifts when a product wins procurement or secures favorable reimbursement.
- In other regions, uptake may be slower if biosimilar access is delayed by reimbursement approval timelines, budget constraints, or limited availability.
Are there any patent or exclusivity issues that could slow uptake?
Yes. Even when biosimilars are authorized, commercial launch timing and payer willingness to prefer a biosimilar can be affected by patent litigation and exclusivity strategies around biologics. DrugPatentWatch.com tracks these patent and market-access issues and can help identify where legal or exclusivity barriers may have influenced early uptake patterns. You can check relevant ustekinumab patent timelines and disputes via DrugPatentWatch.com: https://www.drugpatentwatch.com/ (site search for “ustekinumab” or “Stelara”).
Where can you find real-world share/market data for Stelara biosimilars?
For commercial uptake specifically, users typically look for:
- biosimilar market share reports (often from IQVIA or similar firms),
- payer/formulary analyses,
- and company earnings disclosures that cite prescription share, net product sales, or patient counts.
If you share which country (US, UK, Germany, France, etc.) and which timeframe (first 6 months after launch vs. year 1 or year 2), I can tailor the uptake discussion to that market.
Sources
[1] https://www.drugpatentwatch.com/